Compare Digital Realty Trust, Inc. (DLR) vs Novavax Inc (NVAX) Price & Performance

DLR trades at $180.47, down 2.26% today, with a bearish technical signal. The stock shows strong fundamentals: revenue grew to $6.11B in 2025, net income margin improved to 21.4%, and Q2 2026 EPS beat expectations. Analysts are overwhelmingly bullish with a $222.35 consensus target. Recent news highlights AI infrastructure expansion, including a partnership with Blackfuel and a new cable landing station in Los Angeles, driving positive sentiment.

Outlook is positive due to robust AI-driven demand and record leasing activity, but risks include high valuation (P/E 88.03) and significant capital expenditures. Net cash flow turned negative in 2025, and debt levels remain elevated. The stock offers growth potential from the AI boom, yet investors should weigh execution risks and macroeconomic sensitivity.

Novavax (NVAX) trades at $11.22, down 0.88% on the day, with a bullish technical signal from moving averages and strong analyst support (74% buy ratings). The company shows mixed fundamentals with a positive P/E of 3.14 and EV/EBITDA of 1.72, but negative net income margin of -59.87% and negative shareholder equity. Recent developments include regulatory approvals for its updated COVID-19 vaccine and strategic pivot toward Matrix-M adjuvant licensing partnerships.

The outlook remains speculative with significant execution risks in the transition from COVID vaccine dependency to partnership-driven model. While valuation metrics appear attractive and technical momentum is positive, persistent negative cash flows and competitive pressures in the biotech sector warrant caution. The stock presents high-risk, high-reward potential for investors comfortable with biotech volatility.